Persson, U <br/><br/>
The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.  [electronic resource] 

 -  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research   
 - 39-46 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1524-4733 
<br/><br/><label>Standard No.: </label>10.1046/j.1524-4733.2000.36027.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Angiogenesis Inducing Agents--economics<br/>Becaplermin<br/>Cost-Benefit Analysis--methods<br/>Diabetic Foot--classification<br/>Humans<br/>Markov Chains<br/>Middle Aged<br/>Platelet-Derived Growth Factor--economics<br/>Proto-Oncogene Proteins c-sis<br/>Severity of Illness Index<br/>Sweden<br/>Treatment Outcome<br/>United States<br/>Wound Healing--drug effects